EUCTR2009-016069-27-Outside-EU/EEA进行中（未招募）不适用
A Prospective, Randomized, Double-Blind, Multicenter Study to Establish the Safety and Tolerability of Doripenem Compared With Cefepime in Hospitalized Children With Bacterial Pneumonia
Janssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium0 个研究点目标入组 140 人开始时间: 2011年9月14日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 140
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1 - Have new or progressive radiographic infiltrate(s) (alveolar, lobar, or consolidation) consistent with a bacterial pneumonia that is not related to cardiac or other disease processes. (Note: subjects with clinically significant pleural effusions may be included if an empyema has been ruled out by a diagnostic sampling of pleural fluid. Chest X-rays obtained within 48 hours before the start of the infusion of the first dose of IV study drug therapy are acceptable for the screening examination. A computed tomography (CT) scan/magnetic resonance imaging (MRI) may be used to supplement a chest X-ray if the chest X-ray is not sufficiently interpretable).
- •2 - Have a clinical presentation compatible with bacterial pneumonia with ALL of the
- •o Fever (oral temperature >38.0C, tympanic temperature >38.3C, or rectal or core temperature >38.8C) or hypothermia (rectal or core temperature <35.0C) AND
- •o Leukocytosis defined as WBC count > or = 15,000 cells/µL OR > or = 15% immature neutrophils, regardless of the total peripheral white cell count OR neutrophil count >1.2 times (x) the upper limit of normal (ULN); OR leucopenia with total WBC count <4500 cells/µL AND
- •o Non-intubated subjects must have at least 2 of the following clinical signs or symptoms:
- •– New onset of LRT secretions, change in character of secretions, or increase in the quantity of secretions or suctioning requirements
- •– Auscultatory findings of pneumonia or consolidation (rales, rhonchi bronchial breath sounds, decreased breath sounds, wheezing, egophony)
- •– Increased work of breathing expressed as presence of retractions, nasal flaring, or grunting
- •– Hypoxemia (partial pressure of oxygen (PO2) <60mm Hg on room air) or oxygen saturation less than 90% on room air
- •– Tachypnea defined as follows:
- •> or = 50 breaths/minute for ages > or = 3 months to < or = 12 months
- •> or = 40 breaths/minute for ages >12 months to < or = 5 years
- •> or = 20 breaths/minute for ages >5 years of age
- •apnea in infants <12 months of age
- •3 - Have a diagnosis of NP ,VAP, or severe CAP defined by the disease-specific criteria
- •specified below:
- •Nosocomial Pneumonia:
- •Subjects with NP must not be intubated or mechanically ventilated and must be hospitalized or reside in a chronic care facility for a minimum of
- •48 hours before being diagnosed with pneumonia.
- •Ventilator-associated pneumonia:
- •Subjects with VAP must be intubated and mechanically ventilated for > or = 48 hours before being diagnosed with pneumonia.
- •Severe community-acquired pneumonia:
- •Subjects with severe CAP must have pneumonia that is neither NP or VAP and must have at least ONE of the following risk factors for more severe disease or infection with a less susceptible pathogen:
- •– a mild to moderately immunocompromised condition including but not limited to diabetes or other metabolic disorder associated with immunosuppression, asplenia, sickle cell disease, mild to moderate neutropenia (ANC of 500 – 1500 cells/mm3), HIV infection not requiring Pneumocystis jirovicei prophylaxis, antibody deficiency syndromes not requiring chronic immunoglobulin replacement therapy, T-cell deficiencies not requiring prophylactic antibiotics or other chronic therapy for the immunodeficiency, phagocytic disorders, and receipt of non-inhaled corticosteroid therapy equivalent to <1 mg/kg of prednisone daily for 14 or more days during the 30 days be
排除标准
- •1 - Have a history of hypersensitivity reactions to carbapenems, cephalosporins, penicillins, or other ß-lactam antibiotics. Note: Subjects with a history of mild non-urticarial skin rash temporally related to but considered not associated with the previous use of ß-lactam antibiotics are permitted to enroll in the study. For such subjects, there must be a description of the rash and documentation by the investigator that upon review of the history it is his/her opinion that the rash was unlikely due to any of the above-mentioned classes of drugs for the subject to qualify for inclusion in the study.
- •2 - Concomitant infection including but not limited to suspected or confirmed meningitis, or other CNS infection, requiring systemic antibiotic or antifungal therapy at the time of randomization. (Clarification: possible bacteremia with a presumed respiratory pathogen is acceptable).
- •3 - Have received more than 24 hours of systemic antibacterial therapy in the 48 hours before the start of the infusion of the first dose of IV study drug therapy.
- •4 - Known presence at baseline of Stenotrophomonas maltophilia or Burkholderia cepacia pulmonary infection
- •5 - Known at the time of randomization to have mono-microbial pneumonia caused by a single pathogen that is nonsusceptible to doripenem or cefepime, including but not limited to MRSA or atypical bacteria.
- •6 - Have acute respiratory distress syndrome (defined by either diffuse bilateral radiographic infiltrates and/or a PaO2 to fraction of inspired oxygen (FiO2) ratio of <200)
- •7 - Acute or chronic renal insufficiency with a baseline CLCR <60 mL/minute or requires dialysis therapy for any reason.
- •8 - Are profoundly immunodeficient and require prophylactic antimicrobial therapy to
- •prevent infection with Pneumocystis jirovicei, Toxoplasma gondii, or herpes viruses,
- •and/or required chronic or intermittent immunoglobulin replacement therapy.
研究者
相似试验
进行中（未招募）
不适用
A Safety and Tolerability Study of Doripenem Compared with Meropenem in Children Hospitalized with Complicated Intra-abdominal InfectionsComplicated Intra-Abdominal InfectionsMedDRA version: 14.0Level: LLTClassification code 10056570Term: Intra-abdominal infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2009-015864-32-LVJanssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium140
进行中（未招募）
不适用
A Safety and Tolerability Study of Doripenem Compared with Cefepime in Children Hospitalized with Complicated Urinary Tract InfectionsEUCTR2009-015953-18-Outside-EU/EEAJanssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium140
进行中（未招募）
1 期
未命名试验EUCTR2012-002862-11-ATCubist Pharmaceuticals LLC, an indirect wholly-owned subsidiary of Merck Sharp & Dohme Corp.726
进行中（未招募）
不适用
A Safety and Tolerability Study of Doripenem Compared with Cefepime in Children Hospitalized with Complicated Urinary Tract InfectionsComplicated Urinary Tract InfectionsMedDRA version: 14.0Level: PTClassification code 10046571Term: Urinary tract infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2009-015953-18-LVJanssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium140
进行中（未招募）
1 期
Assessment of the Safety Profile and Efficacy of Ceftolozane/TazobactamVentilated Nosocomial PneumoniaMedDRA version: 20.1Level: LLTClassification code 10052596Term: Nosocomial pneumoniaSystem Organ Class: 100000004862EUCTR2012-002862-11-CZCubist Pharmaceuticals LLC726